Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

Subjects:

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects:

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Patient characteristics before and after propensity score matching. by Anna D. Ware (19688153)

Subjects:

Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute th... by Anna D. Ware (19688153)

Subjects:

Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disor... by Anna D. Ware (19688153)

Subjects:

Patient flowchart. by Anna D. Ware (19688153)

Subjects:

Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date. by Anna D. Ware (19688153)

Subjects:

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Analysis of the significantly different metabolomic features. by Bhuripit Saraphol (20855573)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)